Cargando…
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
BACKGROUND: Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by these drugs and their severity especially in patients with history of inflammatory...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240303/ https://www.ncbi.nlm.nih.gov/pubmed/28105370 http://dx.doi.org/10.1186/s40425-016-0205-2 |